Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares (2024 - 2025)

Spyre Therapeutics (SYRE) has disclosed Preferred Shares for 4 consecutive years, with $146.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Preferred Shares changed 0.0% year-over-year to $146.4 million, compared with a TTM value of $146.4 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $9.4 million, down 94.92% over the prior year.
  • Preferred Shares was $146.4 million for Q3 2025 at Spyre Therapeutics, up from $9.4 million in the prior quarter.
  • Across five years, Preferred Shares topped out at $184.9 million in Q4 2023 and bottomed at $9.4 million in Q2 2024.
  • Average Preferred Shares over 3 years is $87.5 million, with a median of $77.9 million recorded in 2024.
  • The sharpest move saw Preferred Shares plummeted 94.92% in 2024, then changed 0.0% in 2025.
  • Year by year, Preferred Shares stood at $184.9 million in 2023, then tumbled by 94.92% to $9.4 million in 2024, then soared by 1458.54% to $146.4 million in 2025.
  • Business Quant data shows Preferred Shares for SYRE at $146.4 million in Q3 2025, $9.4 million in Q2 2025, and $9.4 million in Q1 2025.